pharmacie et médicaments – Déremboursement des médicaments thérapeutiques d'Alzheimer

This written question concerns the reimbursement status of therapeutic drugs for Alzheimer's disease in France. It seeks clarification on the national policy regarding access to these treatments. The question affects patients with Alzheimer's disease, their families, and healthcare providers involved in their care. It may influence future decisions on drug pricing and accessibility.